Zoar Debuts on the New York Stock Exchange Following Landmark Healthcare Merger

Zoar Debuts on the New York Stock Exchange Following Landmark Healthcare Merger

2026-11-18 companies

New York, Wednesday, 18 November 2026.
Impact Biomedical completed its strategic combination with Zoar Limited, debuting on the public market today backed by Zoar Labs’ $77.7 million annual net income and accelerating pipeline commercialization.

A Strategic Merger Creates a New Public Biopharma Player

On November 13, 2026, shareholders of Impact Biomedical Inc. (NYSE American: IBO) formally approved a multi-party business combination with Zoar Limited and Zoar Labs Limited, culminating in a landmark public listing on the NYSE American [1]. The transaction, which was first proposed in June 2025 and underwent multiple amendments through August 2026, was approved by a decisive vote of 7,713,011 shares in favor—representing 89.29% of eligible shares—with only 2,002 votes against [1]. The newly combined entity, now operating as Zoar USA Inc., has inherited Impact Biomedical’s NYSE American listing under the ticker symbol IBO, while Zoar Limited’s ordinary shares are expected to commence trading today under the new ticker symbol “ZOAR” [2].

Financial Backbone and Leadership Transition

Zoar Limited’s financial performance provides a robust foundation for its public debut. For the fiscal year ended March 31, 2026, Zoar Labs reported $651.7 million in revenue, a 17.086% year-over-year increase, and $77.7 million in net income, a 23.923% rise from the prior period [2]. This financial momentum aligns with the strategic vision of DSS, Inc., which completed the business combination to accelerate the commercialization of proprietary biomedical assets and pipeline candidates [2]. Following the merger, DSS will continue trading under its existing NYSE American ticker “DSS,” and further financial disclosures regarding the transaction’s impact on its investment portfolio will be made through upcoming SEC filings [2]. Leadership remains anchored by Jason Grady, CEO of DSS, who emphasized the milestone’s significance in advancing the company’s healthcare investments [2].

Shareholder Confidence and Governance Reinforcement

The overwhelming shareholder support for the merger reflects strong confidence in the combined entity’s future. In addition to approving the merger, shareholders elected a new board of eight directors and ratified Grassi and Co. Certified Public Accountants, P.C. as the independent auditor for the fiscal year ending December 31, 2026 [1]. Frank D. Heuszel received the highest vote count among directors with 7,711,539 votes, while Chan Heng Fai Ambrose received 7,579,387 votes [1]. Executive compensation was approved on an advisory basis, and the amended corporate documents were adopted with 7,600,533 votes in favor [1]. These governance actions underscore a commitment to transparency and long-term value creation.

Market Debut and Next Steps for Zoar

Zoar Limited’s ordinary shares are set to begin trading on the NYSE American under the ticker symbol “ZOAR” on November 18, 2026, marking the public debut of the newly formed biopharmaceutical enterprise [2]. This listing represents a critical liquidity and capitalization milestone for DSS’s healthcare investment strategy and positions Zoar to accelerate the development of its proprietary biomedical pipeline [2]. While the merger does not alter DSS’s existing ticker symbol “DSS,” investors will now have direct access to Zoar’s growth trajectory through its public equity offering [2]. Further updates regarding the transaction’s financial implications will be disclosed via SEC filings in the coming weeks.

Sources


Biotechnology Mergers